ODI Pharma AB (ODI.ST)

SEK 2.28

(-0.87%)

Net Debt Summary of ODI Pharma AB

  • ODI Pharma AB's latest annual net debt in 2023 was -2.63 Million SEK , up 59.37% from previous year.
  • ODI Pharma AB's latest quarterly net debt in 2023 FY was -2.63 Million SEK , up 59.37% from previous quarter.
  • ODI Pharma AB reported annual net debt of -6.49 Million SEK in 2022, up 11.88% from previous year.
  • ODI Pharma AB reported annual net debt of -7.36 Million SEK in 2021, up 49.62% from previous year.
  • ODI Pharma AB reported quarterly net debt of -6.52 Million SEK for 2023 Q2, down -27.18% from previous quarter.
  • ODI Pharma AB reported quarterly net debt of -2.63 Million SEK for 2023 Q4, up 55.51% from previous quarter.

Annual Net Debt Chart of ODI Pharma AB (2023 - 2018)

Historical Annual Net Debt of ODI Pharma AB (2023 - 2018)

Year Net Debt Net Debt Growth
2023 -2.63 Million SEK 59.37%
2022 -6.49 Million SEK 11.88%
2021 -7.36 Million SEK 49.62%
2020 -14.62 Million SEK 28.71%
2019 -20.51 Million SEK -364.06%
2018 -4.42 Million SEK 0.0%

Peer Net Debt Comparison of ODI Pharma AB

Name Net Debt Net Debt Difference
AcuCort AB -19.24 Million SEK 86.292%
AlzeCure Pharma AB (publ) -29.1 Million SEK 90.935%
BioGaia AB (publ) -1.53 Billion SEK 99.828%
Enzymatica AB (publ) 17.73 Million SEK 114.872%
Enorama Pharma AB (publ) -5.71 Million SEK 53.859%
Gabather AB (publ) -1.11 Million SEK -136.583%
Klaria Pharma Holding AB (publ.) 17.68 Million SEK 114.916%
Moberg Pharma AB (publ) -55.81 Million SEK 95.274%
Nanexa AB (publ) -61.13 Million SEK 95.685%
Newbury Pharmaceuticals AB (publ) -15.3 Million SEK 82.762%
Orexo AB (publ) 302.8 Million SEK 100.871%
Probi AB (publ) -275.85 Million SEK 99.044%
Swedencare AB (publ) 1.42 Billion SEK 100.186%
Swedish Orphan Biovitrum AB (publ) 19.58 Billion SEK 100.013%
Toleranzia AB -17.45 Million SEK 84.887%
Vivesto AB -1.29 Million SEK -103.072%